<DOC>
	<DOCNO>NCT01055821</DOCNO>
	<brief_summary>The primary objective protocol study effect standard care hepatitis C ( pegylated interferon ribavirin ) associate therapeutic vaccine TG4040 viral load treatment-naïve patient chronic genotype 1 hepatitis C infection .</brief_summary>
	<brief_title>Efficacy Therapeutic Vaccine TG4040 Combined With Pegylated Interferon Ribavirin Chronic HCV Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Chronically infected patient Hepatitis C virus Genotype 1 ( 1a 1b ) detectable viremia ( HCV RNA blood ) 6 month naïve treatment ; Patients must compensate liver disease , history ascites , jaundice , hepatic encephalopathy bleed esophageal gastric varix require betablockers ; No histological evidence hepatic cirrhosis ( include compensate cirrhosis ) base liver biopsy take within 24 month prior baseline ; FibroScan® perform within 6 month prior treatment indicate absence liver cirrhosis , i.e. , stage &lt; F4 ( METAVIR ) ; case available result , liver biopsy perform prior treatment ; All laboratory parameter must grade 0 1 ( per CTCAE criterion ) except alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , gamma glutamyl transferase ( GGT ) alkaline phosphatase ( ALP ) grade 2 allow state non clinically significant ; No coinfection Human Immunodeficiency Virus ( HIV ) hepatitis B virus ( HBsAg positive ) ; No intravenous ( IV ) drug alcohol abuse ; Serum thyroid stimulate hormone ( TSH ) level within normal range , regardless treatment Lthyroxin ; Normal electrocardiogram ( ECG ) ; Normal retinal examination ( eye fundus ) within last 12 month diabetic patient patient suffer high blood pressure ; Negative pregnancy test woman childbearing potential ( woman two year postmenopausal surgically sterile consider childbearing potential ) ; Female patient female partner male patient ( childbearing potency ) must agree use two effective method birth control study 6 month end treatment . One method need 'barrier ' method ( condom diaphragm ) ; Prior treatment hepatitis C ; Malignancy within last 5 year ; except patient history squamous cell skin cancer basal cell skin cancer enrol , unless patient history skin cancer vaccination site ; Diagnosed suspect hepatocellular carcinoma ; History psychiatric condition include , limited , psychosis , suicidal ideation , major depression . Patients mild moderate depression past prior history suicidal gesture attempt may enrol , Investigator 's opinion , suitable treatment ; Serious , concomitant medical disorder , include active systemic infection proven suspect immunosuppressive disorder ; History immunodeficiency autoimmune disease include autoimmune hepatitis , allogenic transplant , preexist autoimmune antibodymediated disease include , limited : systemic lupus erythematosus , rheumatoid arthritis , multiple sclerosis , Sjogren 's syndrome , autoimmune thrombocytopenia ; Administration vaccine immunoglobulin within 30 day first dose TG4040 /SOC ; Significant cardiovascular disease ( e.g. , New York Heart Association [ NYHA ] class 3 congestive heart failure ; myocardial infarction within past 6 month ; unstable angina ; coronary angioplasty within past 6 month ; uncontrolled arterial ventricular cardiac arrhythmia ) ; Systemic corticosteroid therapy immunosuppressive/immunomodulating drug ( e.g . Cyclosporine ) within 2 month prior first TG4040/SOC administration ; corticosteroid nasal spray , inhaled steroid asthma and/or topical steroid allow ; Any know allergy interferon ( IFN ) , RBV and/or excipients ; Any medical contraindication IFN and/or RBV ; Any know allergy egg ; Women breastfeeding ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Vaccine</keyword>
	<keyword>HCVac</keyword>
	<keyword>MVA-HCV</keyword>
</DOC>